A detailed history of Simplex Trading, LLC transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Simplex Trading, LLC holds 3,217 shares of RAPT stock, worth $2,670. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,217
Previous 2,993 7.48%
Holding current value
$2,670
Previous $9,000 33.33%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$1.76 - $3.75 $394 - $840
224 Added 7.48%
3,217 $6,000
Q2 2024

Jul 25, 2024

SELL
$2.89 - $9.38 $141,997 - $460,876
-49,134 Reduced 94.26%
2,993 $9,000
Q1 2024

Apr 25, 2024

BUY
$6.87 - $26.45 $358,112 - $1.38 Million
52,127 New
52,127 $468,000
Q3 2023

Nov 01, 2023

BUY
$16.34 - $24.66 $10,310 - $15,560
631 Added 1660.53%
669 $11,000
Q2 2023

Aug 04, 2023

SELL
$16.06 - $21.61 $30,160 - $40,583
-1,878 Reduced 98.02%
38 $0
Q1 2023

Apr 27, 2023

BUY
$17.19 - $30.8 $32,936 - $59,012
1,916 New
1,916 $35,000
Q1 2022

May 02, 2022

SELL
$17.02 - $40.22 $72,930 - $172,342
-4,285 Closed
0 $0
Q4 2021

Feb 23, 2022

SELL
$29.5 - $39.5 $1.28 Million - $1.72 Million
-43,499 Reduced 91.03%
4,285 $157,000
Q3 2021

Oct 28, 2021

BUY
$29.86 - $39.47 $92,566 - $122,357
3,100 Added 6.94%
47,784 $1.47 Million
Q2 2021

Aug 12, 2021

BUY
$17.99 - $40.02 $803,865 - $1.79 Million
44,684 New
44,684 $1.42 Million
Q1 2021

Apr 26, 2021

SELL
$16.0 - $24.46 $20,912 - $31,969
-1,307 Closed
0 $0
Q4 2020

Feb 02, 2021

BUY
$15.89 - $40.87 $20,768 - $53,417
1,307 New
1,307 $25,000

Others Institutions Holding RAPT

About RAPT Therapeutics, Inc.


  • Ticker RAPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,656,600
  • Market Cap $24.6M
  • Description
  • RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...
More about RAPT
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.